Metastatic perirectal PEComa treated by checkpoint inhibitor immunotherapy and multimodal treatment: case report and review of the literature.

PEComa immunotherapy perivascular epithelioid cell selective internal radiation therapy targeted therapy

Journal

Therapeutic advances in medical oncology
ISSN: 1758-8340
Titre abrégé: Ther Adv Med Oncol
Pays: England
ID NLM: 101510808

Informations de publication

Date de publication:
2024
Historique:
received: 01 05 2024
accepted: 19 08 2024
medline: 24 9 2024
pubmed: 24 9 2024
entrez: 24 9 2024
Statut: epublish

Résumé

Malignant PEComas are an extremely rare subtype of soft tissue sarcomas. Here, we report the case of a man presenting with a perirectal PEComa and liver metastasis. Since the tumor harbored a tumor mutational burden of 23/Mb and a programmed death-ligand 1 tumor positivity score of 50%, the patient was treated with pembrolizumab as a second line of systemic therapy, in combination with everolimus. This combined therapy led to a near-complete response of the primary tumor and a partial response of the metastasis. Radioembolization of the liver metastasis was performed due to isolated liver progression, and the pelvic tumor was treated by radiotherapy because of pelvic symptoms. The disease is still stable after 13 months of pembrolizumab plus everolimus and multimodal treatment. This case shows that malignant PEComas can display molecular features associated with sensitivity to checkpoint inhibitors. The use of checkpoint inhibitors may be a relevant therapeutic strategy in these patients. It is also the first report on selective internal radiation therapy in PEComas. A case of a patient with metastatic PEComa of the rectum, a very rare tumor type, treated by immunotherapy in combination with local treatments This article reports the case of a patient presenting with a very rare tumor type called “PEComa”. The tumor originated from the rectum and had disseminated to the liver. Since this tumor is very rare, there is a lack of knowledge on which treatments to use, and every case reporting the use of new treatments in PEComas is helpful. Here, the tumor displayed molecular alterations that suggested that it would respond to immunotherapy, such as a high number of mutations. Therefore, the patient was treated with an immunotherapy called pembrolizumab, in combination with another medication (everolimus). The rectal tumor nearly disappeared under treatment, and the liver metastasis decreased in size. The patient had radiotherapy of the rectum because of rectal bleeding. For the liver metastasis we used another technique called radioembolization, that consists in delivering radioactive compounds directly in the metastasis through the bloodstream. Now, he has received immunotherapy for 13 months and the disease is still under control. This case shows that immunotherapy can be a good treatment option in PEComas. It is also the first time that a medical team reports the using radioembolization to treat a PEComa.

Autres résumés

Type: plain-language-summary (eng)
A case of a patient with metastatic PEComa of the rectum, a very rare tumor type, treated by immunotherapy in combination with local treatments This article reports the case of a patient presenting with a very rare tumor type called “PEComa”. The tumor originated from the rectum and had disseminated to the liver. Since this tumor is very rare, there is a lack of knowledge on which treatments to use, and every case reporting the use of new treatments in PEComas is helpful. Here, the tumor displayed molecular alterations that suggested that it would respond to immunotherapy, such as a high number of mutations. Therefore, the patient was treated with an immunotherapy called pembrolizumab, in combination with another medication (everolimus). The rectal tumor nearly disappeared under treatment, and the liver metastasis decreased in size. The patient had radiotherapy of the rectum because of rectal bleeding. For the liver metastasis we used another technique called radioembolization, that consists in delivering radioactive compounds directly in the metastasis through the bloodstream. Now, he has received immunotherapy for 13 months and the disease is still under control. This case shows that immunotherapy can be a good treatment option in PEComas. It is also the first time that a medical team reports the using radioembolization to treat a PEComa.

Identifiants

pubmed: 39314916
doi: 10.1177/17588359241280541
pii: 10.1177_17588359241280541
pmc: PMC11418325
doi:

Types de publication

Case Reports Journal Article

Langues

eng

Pagination

17588359241280541

Informations de copyright

© The Author(s), 2024.

Déclaration de conflit d'intérêts

The authors declare that there is no conflict of interest.

Auteurs

Maxime Rémond (M)

Department of Pathology, Saint Louis Hospital, Assistance Publique - Hôpitaux de Paris, Université Paris Cité, Paris, France.

Atanas Pachev (A)

Department of Radiology, Saint Louis Hospital, Assistance Publique - Hôpitaux de Paris, Université Paris Cité, Paris, France.

Maxime Battistella (M)

Department of Gastroenterology, Saint Louis Hospital, Assistance Publique - Hôpitaux de Paris, Université Paris Cité, 1 Avenue Claude Vellefaux, Paris 75010, France.

Camille Gandon (C)

Department of Pathology, Saint Louis Hospital, Assistance Publique - Hôpitaux de Paris, Université Paris Cité, Paris, France.

Samia Mourah (S)

Department of Tumor Genomics and Pharmacology, Saint Louis Hospital, Assistance Publique - Hôpitaux de Paris, Université Paris Cité, Paris, France.

Isabelle Madelaine (I)

Department of Pharmacy, Saint Louis Hospital, Assistance Publique - Hôpitaux de Paris, Université Paris Cité, Paris, France.

Léon Maggiori (L)

Department of Surgery, Saint Louis Hospital, Assistance Publique - Hôpitaux de Paris, Université Paris Cité, Paris, France.

Bethsabée Benadon (B)

Department of Radiotherapy, Saint Louis Hospital, Assistance Publique - Hôpitaux de Paris, Université Paris Cité, Paris, France.

Nassim Hammoudi (N)

Department of Gastroenterology, Saint Louis Hospital, Assistance Publique - Hôpitaux de Paris, Université Paris Cité, Paris, France.
INSERM U1160, Institut de Recherche Saint-Louis, Université Paris Cité, Paris, France.

Nelson Lourenço (N)

Department of Gastroenterology, Saint Louis Hospital, Assistance Publique - Hôpitaux de Paris, Université Paris Cité, Paris, France.

Thomas Aparicio (T)

Department of Gastroenterology, Saint Louis Hospital, Assistance Publique - Hôpitaux de Paris, Université Paris Cité, Paris, France.
INSERM U1160, Institut de Recherche Saint-Louis, Université Paris Cité, Paris, France.

Classifications MeSH